Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer

J Clin Lab Anal. 2020 Sep;34(9):e23403. doi: 10.1002/jcla.23403. Epub 2020 Jun 2.


Background: Numerous studies have assessed the association between xeroderma pigmentosum complementation group C (XPC) polymorphisms and susceptibility of prostate cancer (PCa); however, the findings remain inconsistent.

Methods: We performed an updated analysis utilizing data from electronic databases to obtain a more accurate estimation of the relationship between XPC rs2228001 A/C polymorphism and PCa risk. We further used in silico tools to investigate this correlation.

Results: Totally, 5,305 PCa cases and 6,499 control subjects were evaluated. When all studies pooled together, we detected no positive result (recessive genetic model: OR = 1.14, 95% CI = 0.93-1.40, Pheterogeneity = 0.001, P = .212); nevertheless, the XPC rs2228001 A/C variant was associated with PCa risk in Asian descendants in the subgroup analysis (OR = 1.21, 95% CI = 1.01-1.43, Pheterogeneity = 0.008, P = .034). In silico tools showed that more than 20 proteins can participate in the protein crosstalk with XPC. The expression of XPC was down-regulated in all Gleason scores of prostate cancer.

Conclusions: The present study indicated that the XPC rs2228001 A/C variant may be associated with elevated PCa risk in Asian patients.

Keywords: XPC; analysis; prostate cancer; variant.